SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

Kodu・Aktsiate loetelu・DBV Technologies SA

D
DBV Technologies SA

Suletud

3.364 -0.53

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.35

Max

3.472

Põhinäitajad
By Trading Economics
Sissetulek	-2.4M -48M
Kasumimarginaal	-1,323.179
Töötajad	161
EBITDA	-4.1M -46M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-3.55% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	29. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-7.7M 1B
Eelmine avamishind	3.89
Eelmine sulgemishind	3.364

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

1.61 / 1.72 Toetus ja vastupanu

DBV Technologies SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. mai 2026, 22:47 UTC

Kuumad aktsiad

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. mai 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. mai 2026, 22:00 UTC

Suurimad hinnamuutused turgudel

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. mai 2026, 18:09 UTC

Suurimad hinnamuutused turgudel

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15. mai 2026, 16:02 UTC

Tulu

Suurimad hinnamuutused turgudel

Forward Industries Shares Fall on New Debt as Solana Value Drops

15. mai 2026, 14:55 UTC

Suurimad hinnamuutused turgudel

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15. mai 2026, 14:43 UTC

Suurimad hinnamuutused turgudel

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15. mai 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. mai 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. mai 2026, 20:19 UTC

Kuumad aktsiad

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. mai 2026, 19:41 UTC

Omandamised, ülevõtmised, äriostud

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. mai 2026, 18:35 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15. mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15. mai 2026, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15. mai 2026, 16:24 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15. mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15. mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15. mai 2026, 15:20 UTC

Tulu

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15. mai 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Võrdlus sarnastega

Hinnamuutus

DBV Technologies SA Prognoos

Hinnasiht

By TipRanks

-3.55% langus

12 kuu keskmine prognoos

Keskmine 3.26 EUR -3.55%

Kõrge 5.5 EUR

Madal 1.01 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi DBV Technologies SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi DBV Technologies SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.61 / 1.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.